Eli Lilly and Company Stock Deutsche Boerse AG

Equities

LLY0

CA28655A1066

Pharmaceuticals

Delayed Deutsche Boerse AG 03:59:01 2024-07-16 am EDT 5-day change 1st Jan Change
22.8 EUR 0.00% Intraday chart for Eli Lilly and Company +3.64% 0.00%
Sales 2024 * 42.98B 39.43B Sales 2025 * 52.79B 48.43B Capitalization 856B 785B
Net income 2024 * 11.94B 10.95B Net income 2025 * 16.59B 15.22B EV / Sales 2024 * 20.4 x
Net Debt 2024 * 20.15B 18.48B Net Debt 2025 * 16.12B 14.79B EV / Sales 2025 * 16.5 x
P/E ratio 2024 *
71.1 x
P/E ratio 2025 *
51.1 x
Employees 43,000
Yield 2024 *
0.55%
Yield 2025 *
0.63%
Free-Float 99.8%
More Fundamentals * Assessed data
Dynamic Chart
1 week+3.64%
Current month+2.70%
1 month+6.54%
3 months+22.58%
More quotes
1 week
22.40
Extreme 22.4
25.00
1 month
21.40
Extreme 21.4
25.00
Current year
18.30
Extreme 18.3
25.20
1 year
18.30
Extreme 18.3
25.20
3 years
18.30
Extreme 18.3
25.20
5 years
18.30
Extreme 18.3
25.20
10 years
18.30
Extreme 18.3
25.20
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 95-12-31
President - -
Chief Tech/Sci/R&D Officer - 23-10-15
Members of the board TitleAgeSince
Director/Board Member 63 21-01-24
Director/Board Member 68 09-03-31
Director/Board Member 64 04-12-31
More insiders
Date Price Change Volume
24-07-16 22.8 0.00% 0
24-07-15 22.8 -8.80% 0
24-07-12 25 +11.61% 1,250
24-07-11 22.4 -0.88% 0
24-07-10 22.6 +2.73% 0

Delayed Quote Deutsche Boerse AG, July 16, 2024 at 03:59 am EDT

More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
950.5 USD
Average target price
893.1 USD
Spread / Average Target
-6.04%
Consensus